|
Market Closed -
Athens S.E.
10:11:13 2026-08-13 EDT
|
5-day change | 1st Jan Change | ||
| 1.560 EUR | -0.64% |
|
-0.76% | +60.82% |
| 06-24 | Lavipharm S.A. announces Annual dividend, payable on July 24, 2026 | CI |
| 05-28 | Lavipharm Q1 earnings before tax from continuing operations EUR1.41 million, up 28.6% Y/Y | RE |
Company Valuation: Lavipharm S.A.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 24.01 | 29.63 | 64.46 | 133.6 | 134.1 | 163.6 |
| Change | - | 23.4% | 117.58% | 107.29% | 0.36% | 22.01% |
| Enterprise Value (EV) 1 | 61.48 | 65.32 | 83.39 | 157.7 | 162.4 | 190.3 |
| Change | - | 6.24% | 27.68% | 89.07% | 3.03% | 17.15% |
| P/E | 11.1x | 17.2x | 9.91x | 71.4x | 14.9x | 27.9x |
| PBR | -1.95x | -2.97x | 1.6x | 3.13x | 2.53x | 2.91x |
| PEG | - | -0.8x | -0.2x | -1x | 0x | -0.8x |
| Capitalization / Revenue | 0.64x | 0.75x | 1.4x | 2.62x | 2.53x | 2.61x |
| EV / Revenue | 1.63x | 1.64x | 1.81x | 3.1x | 3.07x | 3.04x |
| EV / EBITDA | 9.72x | 11.3x | 16.9x | 19.7x | 17.9x | 14.7x |
| EV / EBIT | 11.7x | 14.5x | 20.6x | 35.9x | 31x | 22.1x |
| EV / FCF | 108x | 24.9x | -2.69x | -33.3x | -34.5x | 116x |
| FCF Yield | 0.93% | 4.01% | -37.2% | -3% | -2.9% | 0.86% |
| Dividend per Share 2 | - | - | - | - | 0.02 | - |
| Rate of return | - | - | - | - | 2.52% | - |
| EPS 2 | 0.1272 | 0.1012 | 0.0387 | 0.0111 | 0.0533 | 0.0348 |
| Distribution rate | - | - | - | - | 37.5% | - |
| Net sales 1 | 37.64 | 39.72 | 46.01 | 50.93 | 52.95 | 62.58 |
| EBITDA 1 | 6.326 | 5.761 | 4.932 | 8.022 | 9.072 | 12.92 |
| EBIT 1 | 5.235 | 4.51 | 4.042 | 4.388 | 5.241 | 8.624 |
| Net income 1 | 2.165 | 1.723 | 0.834 | 1.871 | 8.982 | 5.986 |
| Net Debt 1 | 37.47 | 35.69 | 18.93 | 24.04 | 28.34 | 26.67 |
| Reference price 2 | 1.410 | 1.740 | 0.384 | 0.796 | 0.795 | 0.970 |
| Nbr of stocks (in thousands) | 17,027 | 17,027 | 167,868 | 167,868 | 168,691 | 168,691 |
| Announcement Date | 4/26/21 | 3/21/22 | 3/27/23 | 3/21/24 | 4/3/25 | 4/23/26 |
1EUR in Million2EUR
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 307M | |
| 35.65x | 6.69x | 23.19x | 0.88% | 48.57B | |
| 19.4x | 2.3x | 10.51x | 1.32% | 40.99B | |
| 27.99x | 3.98x | 16.37x | 0.6% | 12.2B | |
| 28.4x | 3.46x | 17.93x | 0.89% | 12.35B | |
| 18.73x | 3.33x | 11.58x | 3.85% | 9.08B | |
| 8.97x | 2.07x | 5.38x | 4.48% | 7.41B | |
| 15.91x | 2.06x | 6.44x | 3.24% | 7.13B | |
| 35.22x | 4.02x | 17.1x | 0.23% | 6.86B | |
| Average | 23.78x | 3.49x | 13.56x | 1.94% | 16.1B | |
| Weighted average by Cap. | 26.35x | 4.14x | 15.81x | 1.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- LAVI Stock
- Valuation Lavipharm S.A.
Select your edition
All financial news and data tailored to specific country editions
